Literature DB >> 2370010

Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine.

K D Bardhan1, P Morris, M Thompson, D S Dhande, R F Hinchliffe, R B Jones, M J Daly, N J Carroll.   

Abstract

Forty five patients with refractory oesophagitis, defined as persisting erosive changes or ulceration despite a minimum of three months' treatment with cimetidine 3.2 g daily or ranitidine 0.9 g daily, were treated in an open trial with omeprazole 40 mg daily for up to eight weeks. Endoscopically defined healing was observed in 73% of patients after four weeks' treatment and in 91% after eight weeks' treatment. Symptoms were completely relieved in 60% of patients, improved in 34%, unchanged in 4%, and worsened in 2%. After healing patients returned to maintenance treatment with cimetidine 1.6-3.2 g daily, depending on the severity of their illness before treatment with omeprazole. By six months and 12 months only 55% and 33% of patients respectively were still in remission. This study suggests that when erosive oesophagitis is refractory to treatment with high dose cimetidine or ranitidine, treatment with omeprazole 40 mg daily for up to eight weeks is effective in inducing healing and relieving symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370010      PMCID: PMC1378527          DOI: 10.1136/gut.31.7.745

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Omeprazole versus ranitidine in erosive oesophagitis.

Authors:  P Zeitoun; N Desjars De Keranroué; J P Isal
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

2.  Effect of omeprazole on lower oesophageal function in normal subjects.

Authors:  T K Chakraborty; J S De Caestecker; A Pryde; R C Heading
Journal:  Aliment Pharmacol Ther       Date:  1987-12       Impact factor: 8.171

3.  Treatment of reflux oesophagitis with ranitidine.

Authors:  I C Wesdorp; W Dekker; E C Klinkenberg-Knol
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

4.  Non-steroidal anti-inflammatory drugs and benign oesophageal stricture.

Authors:  S R Heller; I W Fellows; A L Ogilvie; M Atkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-17

5.  Refractory duodenal ulcer.

Authors:  K D Bardhan
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

6.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

7.  Healing and relapse of reflux esophagitis during treatment with ranitidine.

Authors:  H R Koelz; R Birchler; A Bretholz; B Bron; Y Capitaine; G Delmore; H F Fehr; I Fumagalli; J Gehrig; J J Gonvers
Journal:  Gastroenterology       Date:  1986-11       Impact factor: 22.682

8.  Oral cimetidine in reflux esophagitis: a double blind controlled trial.

Authors:  E Wesdorp; J Bartelsman; K Pape; W Dekker; G N Tytgat
Journal:  Gastroenterology       Date:  1978-05       Impact factor: 22.682

9.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

10.  Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.

Authors:  T Havelund; L S Laursen; E Skoubo-Kristensen; B N Andersen; S A Pedersen; K B Jensen; C Fenger; F Hanberg-Sørensen; K Lauritsen
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09
View more
  16 in total

Review 1.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  Treatment of gastro-oesophageal reflux disease in adults. Efficacy of surgery needs to be compared with that of proton pump inhibitors.

Authors:  O Chassany; J F Bergmann; C Caulin
Journal:  BMJ       Date:  1999-01-02

Review 3.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

4.  Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.

Authors:  I C Wesdorp; W Dekker; H P Festen
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 6.  Alkaline reflux oesophagitis.

Authors:  D L Stoker; J G Williams
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

7.  Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy.

Authors:  M J Collen; D A Johnson; M J Sheridan
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

Review 8.  Maintenance therapy: is there still a place for antireflux surgery?

Authors:  D Armstrong; M Nicolet; P Monnier; G Chapuis; M Savary; A L Blum
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

9.  Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.

Authors:  S Cucchiara; R Minella; C Iervolino; M T Franco; A Campanozzi; M Franceschi; F D'Armiento; S Auricchio
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

Review 10.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.